Role of Lifespan Intervention on the Regulation and Progression of Alzheimer's Disease
Role of Lifespan Intervention on the Regulation and Progression of Alzheimer's Disease
批准号:
10376882
负责人:
Stacey J Rizzo
金额:
$99.03万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-06-01 至 2025-03-31
关键词:
2-arachidonylglycerol5&apos-AMP-activated protein kinaseAgeAgingAlzheimer&aposs DiseaseAlzheimer&aposs disease modelAlzheimer&aposs disease riskAmericanAnti-Inflammatory AgentsArachidonic AcidsAstrocytesAutophagocytosisBiochemicalBiological MarkersBiological ModelsBiology of AgingBrainCardiovascular DiseasesCellsClinical TrialsDataDiabetes MellitusDiseaseDisease ProgressionEndocannabinoidsEnzymesEvaluationFRAP1 geneGeneticGenetic ModelsGenetic RiskGoalsImmuneIndividualInflammationInterventionLate Onset Alzheimer DiseaseLipaseLongevityMalignant NeoplasmsModelingMolecularMonoacylglycerol LipasesMutationNeurodegenerative DisordersNeuronsOnset of illnessPathogenesisPathologicPathologyPathway interactionsPatientsPharmaceutical PreparationsPharmacologyPopulationPre-Clinical ModelPrevalencePreventionProcessProphylactic treatmentProtein KinasePublic HealthRegulationResearchRoleSignal TransductionSirolimusSymptomsTREM2 geneTestingTherapeuticTherapeutic Agentsapolipoprotein E-4attenuationcell typecomorbiditydisorder preventionearly onsetexperimental studygenetic approachgenetic risk factorhealthspanhealthy aginghigh riskimmunoregulationimprovedinhibitorinnovationinsightmTOR InhibitormTOR inhibitionmouse modelneuroinflammationneuroprotectionnormal agingnovelnovel therapeutic interventionnovel therapeuticspreventprophylacticrisk variantsystemic inflammatory responsetool
中文摘要
项目摘要/摘要
我们的长期目标是找到能够预防阿尔茨海默病发病机制的治疗药物
(Ad)。AD病例在全球范围内急剧上升,迫切需要开发新的
比目前批准的四种治疗AD的药物更有效的治疗方法,这些药物只提供少量的
症状缓解。到目前为止,所有的临床试验都未能证明阿尔茨海默病的疾病修正效果,这
部分原因可能是我们对AD发病机制的了解有限,以及
不同于正常的健康衰老。我们建议的总体目标是进一步了解
自噬-炎症网络渐进性调节失调的机制
随着年龄的增长而失调,并因病理状况而加速。全身性炎症是这方面的一个生物标志物
调节失调,如它在包括心血管疾病在内的许多与衰老有关的疾病中的流行,
糖尿病、癌症和神经退行性疾病的神经炎症,如阿尔茨海默病(AD)。我们
假设驱动全身性炎症的机制在衰老的生物学和
AD并建议针对全身炎症的共同特征的干预措施,通过调节
自噬-炎症网络可能有可能作为预防转化的治疗剂
研究阿尔茨海默病的发病机制,以及提高老龄人群的健康寿命和寿命。为了这个
我们将使用遗传学和药理学工具的组合来了解大脑中特定的细胞
类型可能参与自噬-炎症网络的调节,通过mTOR依赖和
调节炎症的非依赖于mTOR的机制。我们的研究结果将提供机械论
在细胞水平上的洞察和进一步研究的创新治疗策略。具体来说,我们将
研究参与mTOR抑制的神经保护作用的单个细胞类型
进展性AD,确认和推广散发性AD对寿命和健康的有益影响的数据
AD加雷帕霉素预防性治疗。关键的是,由于年龄和遗传因素是导致
AD,我们将评估包含衰老和遗传风险的临床前模型系统中的干预措施
AD的影响因素。因此,我们将测试AMPK的直接操作在调节寿命和
在正常衰老和AD易感模型中的健康寿命以及MAG脂肪酶抑制在
正常健康衰老和AD发病机制中雷帕霉素与雷帕霉素作用的比较
晚发性AD。
英文摘要
Project Summary/Abstract
Our long-term goal is to identify therapeutic agents that can prevent the pathogenesis of Alzheimer’s disease
(AD). The number of AD cases is rising dramatically worldwide, and there is an urgent need to develop new
therapies that are more efficacious than the four currently approved drugs for AD which provide only modest
symptomatic relief. Every clinical trial to date has failed to demonstrate disease-modifying efficacy for AD, which
may in part be due to our limited understanding of the mechanisms that precede the pathogenesis of AD, and
that are distinct from normal healthy aging. The overall aims of our proposal are to further understand the
mechanisms underlying dysregulation of the autophagy-inflammation network that becomes progressively
dysregulated with age, and accelerated by pathological conditions. Systemic inflammation is a biomarker of this
dysregulation, as exemplified by its prevalence in many aging-related disorders including cardiovascular disease,
diabetes, cancers, and neuroinflammation in neurodegenerative disorders such Alzheimer’s disease (AD). We
hypothesize that mechanisms which drive systemic inflammation are common to both the biology of aging and
AD and propose that interventions which target the shared feature of systemic inflammation, via regulation of
the autophagy-inflammation network, may have potential as therapeutic agents for the prevention of conversion
to disease pathogenesis in AD, as well as improve healthspan and longevity in aging populations. For this
proposal we will use a combination of genetic and pharmacological tools to understand which brain specific cell
types may be involved in the regulation of the autophagy-inflammation network via both mTOR dependent and
mTOR-independent mechanisms that modulate inflammation. Findings from our studies will provide mechanistic
insights at a cellular level and innovative therapeutic strategies for further research. Specifically, we will
investigate the individual cell types that contribute to the neuroprotective effects of mTOR inhibition in
progressive AD, and confirm and extend the data on the beneficial effects of lifespan and healthspan in sporadic
AD with prophylactic treatment of rapamycin. Critically, since age and genetics are the leading risk factors for
AD, we will evaluate interventions in preclinical model systems that incorporate both aging and genetic risk
factors for AD. We will therefore test the role of direct manipulation of AMPK on modulation of lifespan and
healthspan in normal aging and in AD susceptible models, and the beneficial role of MAG lipase inhibition in
normal healthy aging and in the pathogenesis of AD in comparison to the effects of rapamycin in a mouse model
of late onset AD.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Project 1: Identification of Early Life molecular determinants of Alzheimer's Disease pathogenesis
-
批准号:10494775
-
项目类别:
-
资助金额:$22.44万
-
财政年份:2022
-
负责人:Stacey J Rizzo
-
依托单位:
Role of Lifespan Intervention on the Regulation and Progression of Alzheimer's Disease
-
批准号:10599253
-
项目类别:
-
资助金额:$82.8万
-
财政年份:2020
-
负责人:Stacey J Rizzo
-
依托单位:
Improving Preclinical Translation in Alzheimer's Disease Research
-
批准号:10469024
-
项目类别:
-
资助金额:$4.94万
-
财政年份:2018
-
负责人:Stacey J Rizzo
-
依托单位:
Improving Preclinical Translation in Alzheimer's Disease Research
-
批准号:10597112
-
项目类别:
-
资助金额:$4.94万
-
财政年份:2018
-
负责人:Stacey J Rizzo
-
依托单位:
Behavioral Phenotyping
-
批准号:9151760
-
项目类别:
-
资助金额:$39.28万
-
财政年份:2016
-
负责人:Stacey J Rizzo
-
依托单位:
国内基金
海外基金
晚期妊娠维持和抑制早产中cAMP信号活化PR的作用机制研究
-
批准号:81300507
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2013
-
负责人:陈黎
-
依托单位: